Hepion Pharmaceuticals, Inc. (CTRVP): Completion of Acquisition or Disposition of Assets
Hepion Pharmaceuticals, Inc. (CTRVP) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Item 1.01 Entry into a Material Definitive Agreement. On October 6, 2026, Hepion Pharmaceuticals, Inc. (the “Company”) entered into a Membership Interest Purchase Agreement (the “Purchase Agreement”) with Gravitas Life Sciences, LLC, a Delaware limited liability company (“GLS”),
How this was made
The 30-second read
Why it matters
The acquisition provides Hepion with a pipeline candidate (GV104) and expands its immunology portfolio, but introduces dilution and integration considerations.
Market read
First‑report 8‑K acquisition adds a new biotech asset, offering a modest trading catalyst for CTRVP.
What to watch
Lock‑up on the issued shares may delay any immediate upside; integration risk of a clinical‑stage subsidiary.
Background
Hepion Pharmaceuticals filed an 8‑K detailing the purchase of Gravitas Life Sciences, a clinical‑stage biotech.
Ticker impact
Hepion Pharmaceuticals completed the acquisition of Gravitas Life Sciences' membership interests, paying $2M cash and issuing stock.
likely modest upside as investors price in the new asset, offset by dilution concerns
Acquisition adds a clinical-stage biotech subsidiary; market typically rewards strategic bolt‑ons, though the 19.99% share cap indicates dilution risk.
Market effects
Adds a biotech asset to Hepion, potentially boosting the immunology/inflammation sub‑sector.
U.S. micro‑cap biotech market may see slight lift.
Limited to niche biotech investors.
Counterpoint
The dilution from issuing up to 19.99% of shares could outweigh the strategic benefit, pressuring the stock.
Key entities
- CompanyHepion Pharmaceuticals, Inc.
Acquirer, public biotech firm.
- CompanyGravitas Life Sciences, LLC
Target subsidiary being acquired.
